Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2001 Jan;75(2):645-53.
doi: 10.1128/JVI.75.2.645-653.2001.

Immunogenicity and protective efficacy of oligomeric human immunodeficiency virus type 1 gp140

Affiliations

Immunogenicity and protective efficacy of oligomeric human immunodeficiency virus type 1 gp140

P L Earl et al. J Virol. 2001 Jan.

Abstract

The biologically active form of the human immunodeficiency virus type 1 (HIV-1) envelope (Env) glycoprotein is oligomeric. We previously described a soluble HIV-1 IIIB Env protein, gp140, with a stable oligomeric structure composed of uncleaved gp120 linked to the ectodomain of gp41 (P. L. Earl, C. C. Broder, D. Long, S. A. Lee, J. Peterson, S. Chakrabarti, R. W. Doms, and B. Moss, J. Virol. 68:3015-3026, 1994). Here we compared the antibody responses of rabbits to gp120 and gp140 that had been produced and purified in an identical manner. The gp140 antisera exhibited enhanced cross-reactivity with heterologous Env proteins as well as greater neutralization of HIV-1 compared to the gp120 antisera. To examine both immunogenicity and protective efficacy, we immunized rhesus macaques with oligomeric gp140. Strong neutralizing antibodies against a homologous virus and modest neutralization of heterologous laboratory-adapted isolates were elicited. No neutralization of primary isolates was observed. However, a substantial fraction of the neutralizing activity could not be blocked by a V3 loop peptide. After intravenous challenge with simian-HIV virus SHIV-HXB2, three of the four vaccinated macaques exhibited no evidence of virus replication.

PubMed Disclaimer

Figures

FIG. 1
FIG. 1
Purification of oligomeric gp140. (A) Superdex-200 A280 elution profile of gp140. The bracketed fractions contain oligomeric gp140, as shown by chemical cross-linking (not shown). These fractions were pooled, concentrated, and used for immunization of macaques. (B) Coomassie blue staining of proteins in the medium of infected cells (Med) and in the purified Env (Olig) from panel A.

References

    1. Baba T W, Liska V, Hofmann-Lehmann R, Vlasak J, Xu W, Ayehunie S, Cavacini L A, Posner M R, Katinger H, Stiegler G, Bernacky B J, Rizvi T A, Schmidt R, Hill L R, Keeling M E, Lu Y, Wright J E, Chou T C, Ruprecht R M. Human neutralizing monoclonal antibodies of the IgG1 subtype protect against mucosal simian-human immunodeficiency virus infection. Nat Med. 2000;6:200–206. - PubMed
    1. Baldridge J R, McGraw T S, Paoletti A, Buchmeier J J. Antibody prevents the establishment of persistent arenavirus infection in synergy with endogenous T cells. J Virol. 1997;71:755–758. - PMC - PubMed
    1. Barnett S W, Rajasekar S, Legg H, Doe B, Fuller D H, Haynes J R, Walker C M, Steimer K S. Vaccination with HIV-1 gp120 DNA induces immune responses that are boosted by a recombinant gp120 protein subunit. Vaccine. 1997;15:869–873. - PubMed
    1. Beddows S, Lister S, Cheingsong R, Bruck C, Weber J. Comparison of the antibody repertoire generated in healthy volunteers following immunization with a monomeric recombinant gp120 construct derived from a CCR5/CXCR4-using human immunodeficiency virus type 1 isolate with sera from naturally infected individuals. J Virol. 1999;73:1740–1745. - PMC - PubMed
    1. Belshe R B, Gorse G J, Mulligan M J, Evans T G, Keefer M C, Excler J L, Duliege A M, Tartaglia J, Cox W I, McNamara J, Hwang K L, Bradney A, Montefiori D, Weinhold K J. Induction of immune responses to HIV-1 by canarypox virus (ALVAC) HIV-1 and gp120 SF-2 recombinant vaccines in uninfected volunteers. NIAID AIDS Vaccine Evaluation Group. AIDS. 1998;12:2407–2415. - PubMed

Publication types

MeSH terms

Substances